Brineura (cerliponase alfa) is an enzyme replacement therapy for the treatment of CLN2 disease, and is typically infused directly into the brain every two weeks. A study recently commenced at Great Ormond Street Hospital London is now investigating the therapeutic potential of administering Brineura into the eyes of a select group of children with the disorder, in an attempt to prevent vision loss.